Latest Capital Funding News

Page 1 of 13
Genetic Signatures has abandoned its proposed merger with Microba Life Sciences after Microba said it lacked the financial capacity to complete the transaction without fresh capital. GSS also declined to provide unsecured working capital funding, leaving the shareholder vote and Takeovers Panel process to be unwound separately.
Ada Torres
Ada Torres
18 Nov 2026
Genetic Signatures has ended its proposed merger with Microba Life Sciences after Microba said it could not complete the transaction without raising more capital. The decision also removes the deal’s shareholder vote and leaves a Takeovers Panel application awaiting clarification.
Ada Torres
Ada Torres
18 Nov 2026
Vitrafy says it has moved from cryopreservation research into commercial execution, with 19 Guardion devices built, new US partnerships and $38.3 million in cash and term deposits. The next test is converting partner evaluations into recurring revenue after a planned FDA Class II listing in the coming weeks.
Victor Sage
Victor Sage
17 Nov 2026
Vulcan Energy has begun civil construction at its commercial Lithium Extraction Plant in Germany, marking the company’s latest major Lionheart milestone. The project remains targeted for first production in the second half of 2028, although the announcement provides no updated capital or funding figures.
Victor Sage
Victor Sage
16 Nov 2026
Tartana Minerals has accelerated exploration after a shareholder-driven leadership overhaul, but its cash runway is shorter than the time to its next major debt maturity. Assays from Nightflower, copper drilling and regional sampling now carry added significance as the company negotiates refinancing and reviews its stalled copper sulphate operation.
Maxwell Dee
Maxwell Dee
30 Oct 2026
The Calmer Co. posted record Q1 FY27 revenue of A$2.44 million, powered by a sharp lift in US wholesale orders and continued Coles and Woolworths growth. But with A$953,000 in cash against quarterly operating outflows of A$755,000, the kava company remains dependent on further funding and sustained sales momentum.
Victor Sage
Victor Sage
30 Oct 2026
Gwardar Resources has begun trading on the ASX after an oversubscribed $6 million IPO, leaving the explorer with a reported $5.63 million cash position at quarter-end. Its first exploration quarter produced no drilling results, but advanced target generation across two Western Australian projects.
Maxwell Dee
Maxwell Dee
30 Oct 2026
Northern Minerals has advanced Browns Range through feasibility, engineering and exploration, but its flagship rare earths project remains stalled at the funding gate. The company missed its 30 September FID target, flagged material uncertainty over its ability to continue as a going concern and warned that Iluka may be able to terminate the project’s supply agreement.
Maxwell Dee
Maxwell Dee
30 Oct 2026
Altoro Metals has entered its next exploration phase with A$3.12 million in cash, fresh drilling underway and a planned 2027 resource update. But its annual report records a A$1.45 million loss, an unchanged mineral resource and a material uncertainty over its ability to fund the path from exploration to mine restart.
Maxwell Dee
Maxwell Dee
30 Oct 2026
Amotiv has cut its FY27 revenue and underlying EBITA outlook by up to 5% after first-quarter revenue fell 5% on weaker vehicle demand and Thailand flooding. The ASX-listed automotive parts group will nevertheless launch another buyback of up to 5% of its shares, betting its depressed valuation will recover.
Victor Sage
Victor Sage
27 Oct 2026
Syrah Resources is set to receive a further US$15 million from the US International Development Finance Corporation before the end of October, providing working and sustaining capital for its Balama graphite operation. The funding comes with a temporary waiver of existing loan defaults, new warrants and no guarantee of further disbursements.
Victor Sage
Victor Sage
26 Oct 2026
Jatcorp’s revenue rose 23% to $38.9 million in FY2026, but weaker margins, negative operating cash flow and a material going-concern uncertainty leave the nutritional products maker’s recovery unfinished. The company ended the year with $5.6 million in cash after a $4.2 million entitlement offer, while Neurio trademark litigation in China remains unresolved.
Victor Sage
Victor Sage
22 Oct 2026

Browse the archive

Full archive